By Fineline Cube BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) announced a multifaceted collaboration agreement with Revolution Medicines, Inc. (NASDAQ: RVMD), combining a clinical collaboration to evaluate combinations of select BeOne clinical‑stage oncology candidates with Revolution Medicines’ four clinical‑stage RAS(ON) inhibitors, and a regional licensing agreement granting BeOne exclusive rights in select Asian markets.
Deal Overview
| Item | Detail |
|---|---|
| Parties | BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) × Revolution Medicines, Inc. (NASDAQ: RVMD) |
| Deal Type | Multifaceted collaboration: clinical collaboration + regional licensing |
| Clinical Scope | Combinations of select BeOne clinical‑stage oncology candidates with any one or more of Revolution Medicines’ four clinical‑stage RAS(ON) inhibitors |
| Licensing Scope | Exclusive development and/or commercialization rights to the four RAS(ON) inhibitors in select Asian markets |
| Announcement Date | 10 Aug 2026 |
Revolution Medicines’ RAS(ON) Inhibitor Portfolio
| Candidate | Selectivity | Stage |
|---|---|---|
| Daraxonrasib | RAS(ON) multi‑selective inhibitor | Clinical stage |
| Zoldonrasib | RAS(ON) G12D‑selective inhibitor | Clinical stage |
| Elironrasib | RAS(ON) G12C‑selective inhibitor | Clinical stage |
| RMC‑5127 | RAS(ON) G12V‑selective inhibitor | Clinical stage |
Clinical Collaboration – Planned Combination Studies
The parties will evaluate and advance combination therapies pairing specific BeOne candidates with Revolution Medicines’ RAS(ON) inhibitors:
| BeOne Candidate | Modality | Planned Combination Partner |
|---|---|---|
| BGB‑58067 | MTA‑cooperative PRMT5 inhibitor | Daraxonrasib or zoldonrasib |
| BG‑T187 | EGFR×MET×MET trispecific antibody | Daraxonrasib or zoldonrasib |
Regional Licensing Agreement – Financial and Territorial Terms
| Component | Detail |
|---|---|
| Licensed Assets | Four clinical‑stage RAS(ON) inhibitors: daraxonrasib, zoldonrasib, elironrasib, RMC‑5127 |
| Licensed Territory | Select Asian markets |
| Rights Granted to BeOne | Exclusive development and commercialization rights — or exclusive commercialization rights, depending on the market |
| Compensation to Revolution Medicines | Development and sales milestone payments + tiered royalties on net sales in the licensed territory |
| Rights Retained by Revolution Medicines | Full development and commercialization rights outside the licensed territory, including Japan and South Korea |
BeOne to Fund Global Registrational Phase 3 Study
As part of the collaboration, BeOne will leverage its differentiated, fully internal clinical development capability to fund and conduct a global registrational Phase 3 clinical study for one of Revolution Medicines’ RAS(ON) inhibitors. Concurrently, Revolution Medicines continues to advance multiple global registrational studies across its portfolio.
Strategic Rationale & Market Impact
- RAS(ON) × Combination Logic: Pairing BeOne’s oncology assets — a PRMT5 inhibitor and a trispecific antibody — with RAS(ON) inhibitors addresses the persistent challenge of resistance and single‑agent limitations in RAS‑driven cancers.
- Asia Access Deal: The licensing agreement gives BeOne exclusive regional rights to a differentiated portfolio spanning multi‑selective and mutation‑specific (G12D, G12C, G12V) RAS(ON) inhibitors — some of the most sought‑after targets in oncology drug development.
- Cost‑Sharing on Pivotal Trials: BeOne’s commitment to fund a global registrational Phase 3 study reduces Revolution Medicines’ development cost burden while deepening BeOne’s involvement in a globally pivotal asset.
- Two‑Way Strategic Fit: For BeOne, the deal expands its late‑stage oncology pipeline and Asian commercial footprint; for Revolution Medicines, it secures a well‑resourced regional partner and milestone/royalty upside while retaining full rights in Japan, South Korea and the rest of the world.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the clinical collaboration’s study outcomes, licensing milestones, and commercial potential of the RAS(ON) inhibitors in the licensed territories. Actual results may differ due to risks including clinical trial results, regulatory decisions, and competitive dynamics.-Fineline Info & Tech